# Ophirex

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ophirex

- Industry: Biotechnology
- Headquarters: Corte Madera, US
- Website: www.ophirex.com
- Total disclosed funding: $16M
- Latest round: Series B (Mar 16, 2022)
- Investors on record: 1

## About

Based in California, US, and founded in 2015, Ophirex, Inc., operates as a biotechnology company. The company was founded by its CSO and President Matthew Lewin, and Jerry Harrison. In January 2023, Ophirex, Inc. raised USD 37 million in Series B funding led by AXA Investment Managers. As of 2022, the company’s CEO is Nancy J. Koch.

Ophirex develops lifesaving antidotes like antivenom for the treatment of snakebites. The company offers Varespladib blocks secretory phospholipase-A2 (sPLA2), which is a drug that is used for the treatment of snakebites and other life-threatening bites and stings.

The company plans to use the funds raised in January 2023 to continue clinical development, make regulatory submissions, and launch its lead drug candidate, Varespladib.

## Funding rounds

- Series B, Mar 16, 2022, $16M — AXA Investment Managers

## Investors

- AXA Investment Managers — Series B